01:36 , Jun 8, 2018 |  BC Innovations  |  Tools & Techniques

NK cell check-in

Until recently, there’s been scarce overlap between the NK cell field and the world of checkpoint inhibitors, with the former focused on cell therapies to kill tumor cells directly and the latter on relieving immune...
22:21 , Dec 1, 2017 |  BC Week In Review  |  Clinical News

Innate sees no development path for lirilumab combo therapies

Innate Pharma S.A. (Euronext:IPH) said efficacy data from a Phase I/II trial of lirilumab (BMS-986015, IPH2102) in combination with Opdivo nivolumab to treat head and neck cancers "did not provide clear evidence of benefit to...
20:42 , Feb 10, 2017 |  BC Week In Review  |  Clinical News

Lirilumab: Ph II EffiKIR data

Top-line data from the double-blind, French Phase II EffiKIR trial in about 150 elderly AML patients in first complete remission showed that maintenance treatment with 0.1 mg/kg lirilumab every 3 months and 1 mg/kg lirilumab...
16:44 , Feb 6, 2017 |  BC Extra  |  Clinical News

Innate's lirilumab fails Phase II AML trial

Innate Pharma S.A. (Euronext:IPH) lost EUR 2.05 (16%) to EUR 11.05 on Monday after it said lirilumab (IPH2102) missed the primary endpoint in the Phase II EffiKIR trial to treat elderly patients with acute myelogenous...
20:30 , Nov 11, 2016 |  BC Week In Review  |  Clinical News

Lirilumab: Ph I/II CA223-001 data

Data from a cohort of 29 evaluable patients with advanced platinum-refractory squamous cell carcinoma of the head and neck (SCCHN) in the open-label, dose-escalation, international Phase I/II CA223-001 trial showed that IV lirilumab every 4...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Clinical News

Lirilumab: Phase II ongoing

A DSMB recommended for the seventh time continuation of the double-blind, placebo-controlled, French Phase II EffiKIR trial evaluating 0.1 and 1 mg/kg lirilumab based on a safety analysis. The trial completed enrollment of about 150...
07:00 , Jul 28, 2016 |  BC Innovations  |  Tools & Techniques

Innate harmony

On the heels of cancer immunotherapy's clinical success, NK cells - a long-known but underappreciated component of the innate immune system - are emerging as the hottest new tool to fight cancer, with the potential...
07:00 , Oct 19, 2015 |  BC Week In Review  |  Clinical News

Lirilumab: Phase II started

Bristol-Myers Squibb began an open-label, U.S. Phase II trial to evaluate 3 mg/kg IV lirilumab on day 1 of each 28-day cycle for up to 24 cycles plus IV Rituxan rituximab for 12 cycles...
07:00 , Oct 5, 2015 |  BC Week In Review  |  Clinical News

Lirilumab: Phase II ongoing

An independent DSMB recommended for the fifth time continuation of double-blind, placebo-controlled, French Phase II EffiKIR trial evaluating 0.1 and 1 mg/kg lirilumab based on a safety analysis. Last year, the trial completed enrollment of...
07:00 , Apr 13, 2015 |  BC Week In Review  |  Clinical News

Lirilumab: Phase II amended

Innate said an independent DSMB recommended stopping treatment in an undisclosed arm of the double-blind, French Phase II EffiKIR trial evaluating 0.1 and 1 mg/kg lirilumab after the DSMB’s fourth assessment showed that the arm...